122701-29-5

Upstream product

• 24498-31-5 (S)-methyl 2-amino-6-(benzyloxycarbonylamino)hexanoate 
• 405-39-0 N,N'-di-[(phenylmethoxy)carbonyl]-L-lysine 
• 501-53-1 benzyl chloroformate 
• 614-02-8 N⁶-[(benzyloxy)carbonyl]-N²-{N ²,N⁶-bis[(benzyloxy)carbonyl]-L-lysyl}-L-lysine 
• 27894-50-4 methyl (2S)-2-amino-6-{[(benzyloxy)carbonyl]amino}hexanoate hydrochloride 
• 13523-84-7 N^α,N^ε-Bis(benzyloxycarbonyl)-L-lysyl-N^ε-(benzyloxycarbonyl)-L-lysine Methyl Ester 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 

Downstream Products

• 120207-81-0 N⁶-benzyloxycarbonyl-N²-[N⁶-benzyloxycarbonyl-N²-(N²,N⁶-bis-benzyloxycarbonyl-L-lysyl)-L-lysyl]-L-lysine 

Relevant academic research and scientific papers

CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.